Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 134

1.

The effect of St John's Wort on the pharmacodynamic response of clopidogrel in hyporesponsive volunteers and patients: increased platelet inhibition by enhancement of CYP3A4 metabolic activity.

Lau WC, Welch TD, Shields T, Rubenfire M, Tantry US, Gurbel PA.

J Cardiovasc Pharmacol. 2011 Jan;57(1):86-93. doi: 10.1097/FJC.0b013e3181ffe8d0.

PMID:
20980920
[PubMed - indexed for MEDLINE]
2.

Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance.

Lau WC, Gurbel PA, Watkins PB, Neer CJ, Hopp AS, Carville DG, Guyer KE, Tait AR, Bates ER.

Circulation. 2004 Jan 20;109(2):166-71. Epub 2004 Jan 5.

PMID:
14707025
[PubMed - indexed for MEDLINE]
Free Article
3.

St. John's Wort in patients non-responders to clopidogrel undergoing percutaneous coronary intervention: a single-center randomized open-label trial (St. John's Trial).

Trana C, Toth G, Wijns W, Barbato E.

J Cardiovasc Transl Res. 2013 Jun;6(3):411-4. doi: 10.1007/s12265-013-9455-2. Epub 2013 Mar 6.

PMID:
23463297
[PubMed - indexed for MEDLINE]
4.

Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel.

Brandt JT, Close SL, Iturria SJ, Payne CD, Farid NA, Ernest CS 2nd, Lachno DR, Salazar D, Winters KJ.

J Thromb Haemost. 2007 Dec;5(12):2429-36. Epub 2007 Sep 26.

PMID:
17900275
[PubMed - indexed for MEDLINE]
5.

The antiplatelet effect of clopidogrel is not attenuated by statin treatment in stable patients with ischemic heart disease.

Vinholt P, Poulsen TS, Korsholm L, Kristensen SR, Hallas J, Damkier P, Mickley H.

Thromb Haemost. 2005 Aug;94(2):438-43.

PMID:
16113837
[PubMed - indexed for MEDLINE]
6.

Atorvastatin reduces the ability of clopidogrel to inhibit platelet aggregation: a new drug-drug interaction.

Lau WC, Waskell LA, Watkins PB, Neer CJ, Horowitz K, Hopp AS, Tait AR, Carville DG, Guyer KE, Bates ER.

Circulation. 2003 Jan 7;107(1):32-7.

PMID:
12515739
[PubMed - indexed for MEDLINE]
Free Article
7.

St John's wort induces both cytochrome P450 3A4-catalyzed sulfoxidation and 2C19-dependent hydroxylation of omeprazole.

Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, Li T, Liu J, Yang TL, Wang D, Zhong XY, Zhou HH.

Clin Pharmacol Ther. 2004 Mar;75(3):191-7.

PMID:
15001970
[PubMed - indexed for MEDLINE]
8.

Platelet aggregation inhibition in patients receiving statins either fully or partially metabolized by CYP3A4.

Polena S, Gupta MP, Shaikh H, Zazzali K, Coplan N, Gintautas J, Labana SS, Soffer D.

Proc West Pharmacol Soc. 2008;51:60-2.

PMID:
19544679
[PubMed - indexed for MEDLINE]
9.

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10 + 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patients.

Giusti B, Gori AM, Marcucci R, Saracini C, Sestini I, Paniccia R, Valente S, Antoniucci D, Abbate R, Gensini GF.

Pharmacogenet Genomics. 2007 Dec;17(12):1057-64.

PMID:
18004210
[PubMed - indexed for MEDLINE]
10.

Cytochrome P450 2C19 681G>A polymorphism and high on-clopidogrel platelet reactivity associated with adverse 1-year clinical outcome of elective percutaneous coronary intervention with drug-eluting or bare-metal stents.

Trenk D, Hochholzer W, Fromm MF, Chialda LE, Pahl A, Valina CM, Stratz C, Schmiebusch P, Bestehorn HP, Büttner HJ, Neumann FJ.

J Am Coll Cardiol. 2008 May 20;51(20):1925-34. doi: 10.1016/j.jacc.2007.12.056.

PMID:
18482659
[PubMed - indexed for MEDLINE]
Free Article
11.

Cytochrome P450 2C19 loss-of-function polymorphism is a major determinant of clopidogrel responsiveness in healthy subjects.

Hulot JS, Bura A, Villard E, Azizi M, Remones V, Goyenvalle C, Aiach M, Lechat P, Gaussem P.

Blood. 2006 Oct 1;108(7):2244-7. Epub 2006 Jun 13.

PMID:
16772608
[PubMed - indexed for MEDLINE]
Free Article
12.

Impact of CYP2C19 polymorphisms on the antiplatelet effect of clopidogrel in an actual clinical setting in Japan.

Jinnai T, Horiuchi H, Makiyama T, Tazaki J, Tada T, Akao M, Ono K, Hoshino K, Naruse Y, Takahashi K, Watanabe H, Kita T, Kimura T.

Circ J. 2009 Aug;73(8):1498-503. Epub 2009 Jun 17.

PMID:
19531897
[PubMed - indexed for MEDLINE]
Free Article
13.

Lipophilic statins interfere with the inhibitory effects of clopidogrel on platelet function--a flow cytometry study.

Neubauer H, Günesdogan B, Hanefeld C, Spiecker M, Mügge A.

Eur Heart J. 2003 Oct;24(19):1744-9.

PMID:
14522569
[PubMed - indexed for MEDLINE]
Free Article
14.

Besides CYP2C19*2, the variant allele CYP2C9*3 is associated with higher on-clopidogrel platelet reactivity in patients on dual antiplatelet therapy undergoing elective coronary stent implantation.

Harmsze A, van Werkum JW, Bouman HJ, Ruven HJ, Breet NJ, Ten Berg JM, Hackeng CM, Tjoeng MM, Klungel OH, de Boer A, Deneer VH.

Pharmacogenet Genomics. 2010 Jan;20(1):18-25. doi: 10.1097/FPC.0b013e328333dafe.

PMID:
19934793
[PubMed - indexed for MEDLINE]
15.

Contribution of gene sequence variations of the hepatic cytochrome P450 3A4 enzyme to variability in individual responsiveness to clopidogrel.

Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Cavallari U, Trabetti E, Sabaté M, Hernández R, Moreno R, Escaned J, Alfonso F, Bañuelos C, Costa MA, Bass TA, Pignatti PF, Macaya C.

Arterioscler Thromb Vasc Biol. 2006 Aug;26(8):1895-900. Epub 2006 Apr 27.

PMID:
16645157
[PubMed - indexed for MEDLINE]
Free Article
16.

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.

Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, Morath T, Schömig A, von Beckerath N, Kastrati A.

Circulation. 2010 Feb 2;121(4):512-8. doi: 10.1161/CIRCULATIONAHA.109.885194. Epub 2010 Jan 18.

PMID:
20083681
[PubMed - indexed for MEDLINE]
Free Article
17.

Differential impacts of CYP2C19 gene polymorphisms on the antiplatelet effects of clopidogrel and ticlopidine.

Maeda A, Ando H, Asai T, Ishiguro H, Umemoto N, Ohta M, Morishima M, Sumida A, Kobayashi T, Hosohata K, Ushijima K, Fujimura A.

Clin Pharmacol Ther. 2011 Feb;89(2):229-33. doi: 10.1038/clpt.2010.268. Epub 2010 Dec 22.

PMID:
21178986
[PubMed - indexed for MEDLINE]
18.

The interaction between St John's wort and an oral contraceptive.

Hall SD, Wang Z, Huang SM, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC.

Clin Pharmacol Ther. 2003 Dec;74(6):525-35.

PMID:
14663455
[PubMed - indexed for MEDLINE]
19.

The effects of laropiprant, a selective prostaglandin D₂ receptor 1 antagonist, on the antiplatelet activity of clopidogrel or aspirin.

Dallob A, Luo WL, Luk JM, Ratcliffe L, Johnson-Levonas AO, Schwartz JI, Dishy V, Kraft WK, De Hoon JN, Van Hecken A, De Lepeleire I, Radziszewski W, Wagner JA, Lai E.

Platelets. 2011;22(7):495-503. doi: 10.3109/09537104.2011.565433. Epub 2011 Apr 28.

PMID:
21526889
[PubMed - indexed for MEDLINE]
20.

Pharmacodynamics and pharmacokinetics of single doses of prasugrel 30 mg and clopidogrel 300 mg in healthy Chinese and white volunteers: an open-label trial.

Small DS, Payne CD, Kothare P, Yuen E, Natanegara F, Teng Loh M, Jakubowski JA, Richard Lachno D, Li YG, Winters KJ, Farid NA, Ni L, Salazar DE, Tomlin M, Kelly R.

Clin Ther. 2010 Feb;32(2):365-79. doi: 10.1016/j.clinthera.2010.02.015.

PMID:
20206794
[PubMed - indexed for MEDLINE]
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk